Sigrid S Skanland
Overview
Explore the profile of Sigrid S Skanland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1196
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yin Y, Xu H, He L, Brown J, Mato A, Aittokallio T, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40085050
Purpose: The management of chronic lymphocytic leukemia (CLL) has significantly improved with targeted therapies. However, many patients experience a suboptimal response. To optimally select the best therapy, predictive biomarkers are...
2.
Wei Q, Foyn H, Landskron J, Wang S, Rye I, Skanland S, et al.
iScience
. 2025 Mar;
28(3):111931.
PMID: 40034859
FoxP3 regulatory T cells (Tregs) are responsible for immune homeostasis by suppressing excessive anti-self-immunity. Tregs facilitate tumor growth by inhibiting anti-tumor immunity. Here, we explored the targeting of FoxP3 as...
3.
Arseni L, Sigismondo G, Yazdanparast H, Hermansen J, Mack N, Ohl S, et al.
Nat Commun
. 2025 Jan;
16(1):1041.
PMID: 39863584
Chronic lymphocytic leukemia is a malignant lymphoproliferative disorder for which primary or acquired drug resistance represents a major challenge. To investigate the underlying molecular mechanisms, we generate a mouse model...
4.
Skanland S, Okkenhaug K, Davids M
Clin Cancer Res
. 2024 Jul;
30(17):3667-3675.
PMID: 38967552
The PI3K signaling pathway regulates key cellular processes and is one of the most aberrantly activated pathways in cancer. The class I PI3K catalytic subunits p110γ and p110δ are highly...
5.
Hermansen J, Yin Y, Rein I, Skanland S
NPJ Precis Oncol
. 2024 May;
8(1):107.
PMID: 38769096
The microenvironment of hematologic cancers contributes to tumor cell survival and proliferation, as well as treatment resistance. Understanding tumor- and drug-induced changes to the immune cell composition and functionality is...
6.
Montoya S, Bourcier J, Noviski M, Lu H, Thompson M, Chirino A, et al.
Science
. 2024 Feb;
383(6682):eadi5798.
PMID: 38301010
Increasing use of covalent and noncovalent inhibitors of Bruton's tyrosine kinase (BTK) has elucidated a series of acquired drug-resistant BTK mutations in patients with B cell malignancies. Here we identify...
7.
Andersen A, Brodersen A, Ayuda-Duran P, Piechaczyk L, Tadele D, Baken L, et al.
Cell Rep Methods
. 2023 Dec;
3(12):100654.
PMID: 38065095
Current treatment selection for acute myeloid leukemia (AML) patients depends on risk stratification based on cytogenetic and genomic markers. However, the forecasting accuracy of treatment response remains modest, with most...
8.
Ayuda-Duran P, Hermansen J, Giliberto M, Yin Y, Hanes R, Gordon S, et al.
Cell Death Discov
. 2023 Dec;
9(1):435.
PMID: 38040674
The principle of drug sensitivity testing is to expose cancer cells to a library of different drugs and measure its effects on cell viability. Recent technological advances, continuous approval of...
9.
Hermansen J, Yin Y, Urban A, Myklebust C, Karlsen L, Melvold K, et al.
Cell Death Discov
. 2023 Apr;
9(1):125.
PMID: 37055391
The microenvironment of chronic lymphocytic leukemia (CLL) cells in lymph nodes, spleen, and bone marrow provides survival, proliferation, and drug resistance signals. Therapies need to be effective in these compartments,...
10.
Giliberto M, Santana L, Holien T, Misund K, Nakken S, Vodak D, et al.
Front Oncol
. 2022 Dec;
12:1040730.
PMID: 36523963
Introduction: Multiple myeloma (MM) is a heterogeneous disease where cancer-driver mutations and aberrant signaling may lead to disease progression and drug resistance. Drug responses vary greatly, and there is an...